size-exclusion chromatography is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-05. Numbers and descriptions here follow the published literature rather than marketing material.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Alexander Bodkin at McLean Hospital, an affiliate of Harvard Medical School, began a collaboration with Somerset to develop delivery of selegiline via a transdermal patch in order to avoid the well known dietary restrictions of MAOIs. Somerset obtained FDA approval to market the patch for depression in 2006. Similarly, the orally disintegrating tablet (ODT) form of selegiline, marketed under the brand name Zelapar, was approved for Parkinson's disease in the United States in 2006 and in the European Union in 2010. Binding to and agonism of the trace amine-associated receptors (TAARs) as the mechanism responsible for the MAE effects of selegiline and related MAEs like PPAP and BPAP was first suggested in the early 2000s following the discovery of the TAARs. Activation of the TAAR1 as the mechanism of the MAE effects was first clearly substantiated in 2022.
Promising results of health and medical research are reported: mouse-tested novel antibiotics class (including Zosurabalpin) against A. baumannii (3 Jan), small-trialed focused ultrasound for blood–brain barrier opening for better medication (Aducanumab) entry against Alzheimer's disease (3 Jan), a review supports the efficacy of exercise against depression (15 Jan), an available blood test to detect Alzheimer's disease with high accuracy using p-tau217 (22 Jan), one of two small-trialed gene therapies against DFNB9-deafness (24 Jan), phase 3-trialed dengue vaccine effective against at least two of four dengue types (31 Jan) Hazard research is published: ~240.000 particles of microplastic and nanoplastics (~90%) per liter are found in samples of plastic-bottled water (8 Jan), a study estimates harmful chemicals used in plastic materials have caused $249 billion U.S. healthcare system costs in 2018 (11 Jan), a study indicates fungal infections may be causing millions more deaths annually than thought (12 Jan), a study of European plastic waste exports to Vietnam finds a large fraction is dumped in nature and suggests air pollution from melting plastics and untreated wastewater have significant impact on health (18 Jan).
Apoptosis A form of programmed cell death involved in development and disease. In the nervous system, apoptosis shapes neural circuits and removes damaged neurons. Arachnoid mater The middle of the three layers of the meninges that surround the brain and spinal cord, located between the dura mater and the pia mater. Arousal A physiological and psychological state of alertness and readiness, regulated by the reticular activating system and neurotransmitters such as norepinephrine and dopamine. Astrocyte A star-shaped glial cell in the central nervous system involved in maintaining the blood–brain barrier, regulating neurotransmitter levels, and supporting neuronal function. Ataxia A neurological symptom characterized by a lack of coordination and balance, typically caused by damage to the cerebellum or its connections. Auditory cortex A part of the temporal lobe responsible for processing auditory information, including pitch, volume, and sound localization. Autonomic nervous system A division of the peripheral nervous system that controls involuntary physiological processes, including heart rate, digestion, and respiration. It is divided into the sympathetic and parasympathetic systems. Axon A long, slender projection of a neuron that conducts action potentials away from the cell body to synaptic terminals, where neurotransmitters are released. Axon hillock The cone-shaped region of a neuron’s soma where the axon originates and action potentials are typically initiated.
The unencapsulated strains are almost always less invasive; however, they can produce an inflammatory response in humans, which can lead to many symptoms. Vaccination with Hib conjugate vaccine is effective in preventing Hib infection but does not prevent infection with NTHi strains. H. influenzae can cause respiratory tract infections including pneumonia, otitis media, epiglottitis (swelling in the throat), eye infections and bloodstream infection, meningitis. It can also cause cellulitis (skin infection), infectious arthritis (inflammation of the joint), and non-gonococcal urethritis (NGU).
Jaw laxity that may make an individual's jaw open and close like a hinge, as well as open further than the average. Neck pain that can lead to chronic headaches and is usually associated with a crackling or grinding sensation (crepitus). The spine may end up in a "round back" or inversely may extend too much into hyperlordosis. Individuals may also experience scoliosis. Joints commonly associated with hypermobility (wrists, knees, ankles, elbows, shoulders) may be at more severe risk to dislocate or strain.
Sources: en.wikipedia.org
Like most brainstem tumors, diagnosing diffuse intrinsic pontine glioma usually involves non-invasive brain imaging like MRI, in addition to neurologic physical exam. Biopsies and other surgical procedures are also used when possible. Similar to DIPG, diffuse midline gliomas (DMG) often fall into similar categories for both diagnosis and treatment as DIPG and are often categorized together. More recently, biopsies are performed so that the best option for clinical trials can be chosen. In studies resulting from the DIPG/DMG Registry and in connection with the DIPG/DMG Collaborative, statistics reveal that approximately 150–300 patients are diagnosed with DIPG in the USA per year, the median age of patients with DIPG is approximately 6–7 years old, and the male/female ratio of DIPG patients is 1:1.
He then attempted to assuage fears that economic sanctions might destroy the economy, and asked Rhodesians to stand firm: "The mantle of the pioneers has fallen on our shoulders ... In the lives of most nations there comes a moment when a stand has to be made for principles, whatever the consequences. This moment has come to Rhodesia ... the first Western nation in the last two decades to say 'so far and no further'." He concluded with an assertion that the declaration of independence was "a blow for the preservation of justice, civilisation and Christianity".
==== Global Compact for Migration ==== On 8 January 2023, Foreign Minister Mauro Vieira announced Brazil rejoined the Global Compact for Migration from which the Bolsonaro government withdrew on 9 January 2019 The UNHCR welcomed the decision stating that ensures "the people's rights and the means so that migrants and refugees can contribute positively to the host countries". According to the Foreign Ministry, the party's mutual benefits of the pact also reflect on the "Brazilian government's commitment to the protection and promotion of the rights of more than 4 million Brazilians living abroad".
In Indian media, Morea has often been referred to as a "Chocolate Boy", a term used to describe his youthful appearance and conventional attractiveness. He dominated and redefined the Indian modeling scene before male modeling was mainstream, gained international recognition, had the perfect look for print and runway, and bridged the gap to Bollywood, influencing generations after him. He has been noted for his commitment to his roles and described as having a versatile screen presence. A 2008 feature in India Today titled "The Boylet Club" identified him as one of Bollywood's "alpha males" of the time. South China Morning Post cited him as one of the top Indian male models who successfully transitioned into acting. In 2025, The Times of India marked him “…the unforgettable 90s heroes who became India’s first big crushes”, describing him as “tall, white, and incredibly handsome”. Motherland magazine regarded him as 'Supermodel of 2000s'. Film critics and journalists have occasionally commented on his style and performances; Onkar Kulkarni of Times of India referred to him as a "stylish superhero," while Taran Adarsh of Bollywood Hungama remarked on his sincerity and screen presence. In February 1999, Morea appeared on the cover of the international edition of Elle magazine. He clinched 13th place on "India's most handsome man" by WebIndia123. He ranked on The Times of India's "50 Most Desirable Men" list for multiple years, including 13th in 2009, and between 30th and 45th place from 2010 to 2014.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.